TME PHARMA PROVIDES UPDATE ON RESOURCES ALLOCATED TO THE
LIQUIDITY CONTRACT WITH INVEST SECURITIES


Berlin, Germany, April 10, 2025, 07.00 p.m. CEST – TME Pharma N.V. (Euronext Growth Paris:
ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment
of cancer by targeting the tumor microenvironment (TME), announced today that it has increased the
resources allocated to the liquidity contract entrusted to Invest Securities by the contribution of €5,000
in cash.

This increase, in accordance with the provisions of article 4 of the Autorité des marchés financiers
(AMF) decision no. 2021-01 of June 22, 2021 (the “AMF Decision”), aims to support the cash balance
and securities resources of the liquidity account.

As of April 10, 2025, after market close and after increasing the cash amount in the liquidity contract
by €5,000, the resources available are as follows:
• Number of shares: 97,807
• Cash balance of the liquidity account: €13,401.54

It is recalled that during the half-year report of December 31, 2024, the following resources
appeared in the liquidity account:
• Number of shares: 73,874
• Cash balance of the liquidity account: €9,914.70


For more information, please contact:

TME Pharma N.V.
Aram Mangasarian, Ph.D., CEO
Tel. +49 (0) 30 16637082 0
investors@tmepharma.com


Investor and Media Relations:

LifeSci Advisors
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com

NewCap
Arthur Rouillé
Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr
About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the
most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor
microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against
the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma’s
approach works in combination with other forms of treatment to weaken tumor defenses and enable
greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, TME Pharma is studying its lead drug
candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer
patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-
line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA
clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally,
GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the
interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even
deeper and more durable responses, and improved survival. US FDA has approved the design of a
randomized Phase 2 trial in glioblastoma and TME Pharma was awarded fast track designation by the
FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the
aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also
previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma
in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety
profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic
cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021.
The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS,
to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two
different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic
cancer. The design of the trial has been approved in the United States. The company’s second clinical-
stage drug candidate, NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related
chemokines), showing potential to address fibrosis and inflammation is evaluated in ophthalmic
diseases with a high need for well-tolerated therapies with anti-fibrotic effect. Further information can
be found at: www.tmepharma.com.

TME Pharma® and the TME Pharma logo are registered trademarks.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit TME Pharma on LinkedIn and X.


About the GLORIA Study

GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination
with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients
with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates
safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy
and bevacizumab.


About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12
combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-
paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.
Disclaimer

Translations of any press release into languages other than English are intended solely as a
convenience to the non-English-reading audience. The company has attempted to provide an accurate
translation of the original text in English, but due to the nuances in translating into another language,
slight differences may exist. This press release includes certain disclosures that contain "forward-
looking statements.” Forward-looking statements are based on TME Pharma’s current expectations
and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors
that could cause actual results to differ include, but are not limited to, the risks inherent in oncology
drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain
regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements
contained in this announcement are made as of this date, and TME Pharma undertakes no duty to
update such information except as required under applicable law.